[Evaluation and care of patients with type Ii diabetes regarding recommendations concerning cardiovascular risk factors and adherence to values in general medicine in the Grand Duchy of Luxembourg].
OBJECTIVE
The objective of this study was to assess the adherence to national guidelines on cardiovascular prevention and target attainment for patients with type 2 diabetes mellitus followed-up in general practice.


METHODS
Non-interventional, cross-sectional survey.


RESULTS
606 patients have been considered in this analysis. Type 2 diabetes patients remain undertreated with statins (63% treated), even so those with a cardiovascular history (80% treated). Although more patients received antihypertensive treatment (82%) compared to hypolipidemic medication (69%), the proportion of patients attaining targets for total (35%), HDL (65%), and LDL-cholesterol (42%) exceeded far those attaining blood pressure control (13%). The primary endpoint of reaching the goal for LDL-cholesterol (<100 mg/dL) was attained by 42% of patients, of which only 13% reached the more stringent target of LDL-C <70 mg/dL. About half of the patients attained glycemic control (HbA1c <7%, 49%) and had triglycerides <150 mg/dL (55%).


CONCLUSIONS
The majority of type 2 diabetes patients are treated for hypercholesterolemia and hypertension, although, there is still undertreatment with statins, especially in patients with CV disease. Only 42% of patients were on target for LDL-cholesterol and 13% for blood pressure. Therefore, wider implementation of process and outcome indicators, which proved to be related, and continuous evaluation of their result, is needed.
Stein
Romain
R
Aubart-Schuller
Monique
M
Vandenberghe
H
H
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000453:epidemiology*; D005194:Family Practice; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D008189:Luxembourg; D008297:Male; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology
D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors